Critical Technology

Nuclear Medicine & Radioisotope Technologies

The capacity to produce and apply medical radioisotopes and radiation technologies, isotope supply, radiopharmaceuticals, and the therapy and imaging systems that depend on a fragile global chain. One of the capabilities of Biotechnology & Health Technologies.

International families: 12k2015 to 2024
Leading country: United States2.1× the next
All families: 26khome filings included
Over five years: Rising2020 to 2024 against the five before

Year by year

Patent families by country of origin and the year of the earliest filing, 2000 to 2025; 2025 is a part year, still filling in. International families are those for which protection was sought beyond one country.

Volume

International patent families in the capability, by the year of the earliest filing.

Source: Global Institute for National Capability (GINC), 2026. Underlying patents from 107 patent offices, IFI CLAIMS and Google

Share by country

Each country's share of the year's international families, in per cent: the capability's five largest countries of origin, 2015 to 2024, and the rest of the world.

Source: Global Institute for National Capability (GINC), 2026. Underlying patents from 107 patent offices, IFI CLAIMS and Google

Country leaderboard

International patent families, 2015 to 2024, by country of origin. Growth compares the latest five full years with the five before.

Ten largest

United States

China

Japan

Germany

South Korea

Switzerland

Netherlands

United Kingdom

Canada

France

4,153

2,013

1,410

792

720

487

414

379

350

284


1	United States	4,153	33.3%	1.0×	5,339
2	China	2,013	16.1%	1.7×	10,937
3	Japan	1,410	11.3%	0.9×	2,606
4	Germany	792	6.3%	1.1×	902
5	South Korea	720	5.8%	1.5×	1,662
6	Switzerland	487	3.9%	2.0×	538
7	Netherlands	414	3.3%	0.5×	420
8	United Kingdom	379	3.0%	0.9×	429
9	Canada	350	2.8%	1.2×	408
10	France	284	2.3%	0.9×	317
11	Sweden	200	1.6%	0.8×	214
12	Belgium	172	1.4%	0.8×	181
13	Taiwan	149	1.2%	0.6×	233
14	Australia	145	1.2%	1.2×	160
15	Israel	122	1.0%	1.1×	148
16	Italy	119	1.0%	0.9×	142
17	Denmark	85	0.7%	1.2×	87
18	Spain	66	0.5%	1.1×	77
19	Norway	48	0.4%	0.8×	54
20	Ireland	41	0.3%	1.7×	45
21	India	37	0.3%	0.8×	45
22	Türkiye	28	0.2%	3.0×	39
23	Singapore	27	0.2%	1.1×	28
24	Czechia	25	0.2%	0.6×	34
25	Russia	24	0.2%	0.3×	314
26	Poland	24	0.2%	1.4×	63
27	Finland	13	0.1%	1.2×	16
28	Austria	13	0.1%	1.2×	19
29	Portugal	13	0.1%	0.4×	15
30	Hungary	13	0.1%	0.9×	14
31	Hong Kong	9	0.1%	3.5×	13
32	Cayman Islands	8	0.1%	0.3×	11
33	South Africa	7	0.1%	0.4×	7
34	Mexico	7	0.1%	0.8×	13
35	Luxembourg	5	0.0%	0.7×	5
36	Brazil	4	0.0%	1.0×	21
37	New Zealand	3	0.0%	0.5×	3
38	Saudi Arabia	3	0.0%	–	15
39	Liechtenstein	1	0.0%	0.0×	1
40	Malaysia	0	0.0%	–	1

Applicants

The largest applicants by international patent families, 2015 to 2024: across the world, then within each of the five countries with the most families in Nuclear Medicine & Radioisotope Technologies. Names are as held in the source and are not consolidated across subsidiaries.

Global

12,474 international families

KONINKLIJKE PHILIPS NV · Netherlands

SHANGHAI UNITED IMAGING HEALTHCARE CO LTD · China

SIEMENS HEALTHINEERS INT AG · Switzerland

SIEMENS HEALTHCARE GMBH · Germany

HITACHI LTD · Japan

Elekta ltd · United Kingdom

318

297

213

186

184

174

United States

4,153 international families

UNIV CALIFORNIA

SIEMENS MEDICAL SOLUTIONS USA INC

UNIV TEXAS

MEMORIAL SLOAN KETTERING CANCER CENTER

VARIAN MED SYS INC

UNIV JOHNS HOPKINS

151

116

101

100

China

2,013 international families

SHANGHAI UNITED IMAGING HEALTHCARE CO LTD

OUR UNITED CORP

NEUBORON THERAPY SYSTEM LTD

ZHONGPENG XIAMEN MEDICAL DEVICES CO LTD

SHENZHEN OUR NEW MEDICAL TECH DEVELOPMENT CO LTD

SHANGHAI UNITED IMAGING MEDICAL TECHNOLOGY CO LTD

279

150

Japan

1,410 international families

HITACHI LTD

CANON MEDICAL SYSTEMS CORP

SUMITOMO HEAVY INDUSTRIES

HITACHI HIGH TECH CORP

NIHON MEDIPHYSICS CO LTD

TOSHIBA ENERGY SYSTEMS & SOLUTIONS CORP

184

152

Germany

792 international families

SIEMENS HEALTHCARE GMBH

Siemens Healthineers Ag

BRAINLAB AG

MERCK PATENT GMBH

SIEMENS HEALTHCARE AG

UNIV MUENCHEN TECH

182

117

South Korea

Japan

Germany

China

South Korea

9,688

6,387

4,131

2,870

1,604

Crosswalk

How Nuclear Medicine & Radioisotope Technologies is matched to the patent classifications. The entries below were chosen for it; each stands for itself and everything beneath it in the scheme, 278 Cooperative entries in all. A patent family counts when any of its codes, in either scheme and at any office, falls under one of them. Codes since retired are placed under the entries that replaced them.

Entry	Title in the scheme	Why it is chosen	CPC codes	IPC codes	Documents
A61K51/00	Preparations containing radioactive substances for use in therapy or testing in vivo	Radiopharmaceuticals	122	10	167,512
G21G	Conversion of chemical elements; radioactive sources	Radioisotope production and radioactive sources	33	15	27,377
H05H6/00	Targets for producing nuclear reactions	Targets for producing isotopes by nuclear reaction	4	1	3,899
H05H13/00	Magnetic resonance accelerators; Cyclotrons	Cyclotrons	8	6	9,596
C07B59/00	Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se	Isotope-labelled organic compounds	7	1	36,094
A61N5/10	X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy	Radiotherapy: X-ray, gamma, particle beams, brachytherapy	85	1	253,426
G01T1/161	Applications in the field of nuclear medicine, e.g. in vivo counting	Radiation detection for nuclear medicine	19	4	28,604
A61B6/037	Emission tomography	Emission tomography (PET, SPECT)	1	none	24,100
G21G5/00	Alleged conversion of chemical elements by chemical reaction	Left out

CPC and IPC codes are the codes in use on patent documents, at any office, that fall under the entry. Documents is the larger of the two schemes' counts of documents carrying one of them. An entry with no IPC codes can be told apart only in the Cooperative scheme.

The Cooperative codes in use that count towards Nuclear Medicine & Radioisotope Technologies: 279 codes on 538,743 documents. The 150 most used are listed; the full list is in the cpc-to-capability.csv download.

Code	Title	Under entry	How placed	Documents
A61B6/037	Emission tomography	A61B6/037	In the scheme	24,100
A61N5/10	X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy	A61N5/10	In the scheme	22,803
C07B59/002	Heterocyclic compounds	C07B59/00	In the scheme	16,807
A61N5/1049	Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam	A61N5/10	In the scheme	15,717
A61K51/088	Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins	A61K51/00	In the scheme	12,636
A61N2005/1087	Ions; Protons	A61N5/10	In the scheme	11,998
A61N5/103	Treatment planning systems	A61N5/10	In the scheme	9,072
A61N5/1048	Monitoring, verifying, controlling systems and methods	A61N5/10	In the scheme	8,921
A61K51/0497	Organic compounds conjugates with a carrier being an organic compounds	A61K51/00	In the scheme	8,400
A61K51/04	Organic compounds	A61K51/00	In the scheme	8,165
A61K51/08	Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins	A61K51/00	In the scheme	8,020
A61K51/1093	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies	A61K51/00	In the scheme	7,287
A61N5/1031	Treatment planning systems using a specific method of dose optimization	A61N5/10	In the scheme	7,171
A61N5/1001	X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy	A61N5/10	In the scheme	6,923
A61N5/1077	Beam delivery systems	A61N5/10	In the scheme	6,885
A61N2005/1061	Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using an x-ray imaging system having a separate imaging source	A61N5/10	In the scheme	6,804
C07B59/001	Acyclic or carbocyclic compounds	C07B59/00	In the scheme	6,650
A61K51/0482	Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA	A61K51/00	In the scheme	6,628
A61N5/1007	Arrangements or means for the introduction of sources into the body	A61N5/10	In the scheme	5,922
A61K51/0455	Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom	A61K51/00	In the scheme	5,861
A61N5/1081	Rotating beam systems with a specific mechanical construction, e.g. gantries	A61N5/10	In the scheme	5,849
A61K51/1027	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants	A61K51/00	In the scheme	5,761
A61N5/1039	Treatment planning systems using functional images, e.g. PET or MRI	A61N5/10	In the scheme	5,759
A61K51/00	Preparations containing radioactive substances for use in therapy or testing in vivo	A61K51/00	In the scheme	5,678
A61N5/1071	Monitoring, verifying, controlling systems and methods for verifying the dose delivered by the treatment plan	A61N5/10	In the scheme	5,638
A61N5/1067	Beam adjustment in real time, i.e. during treatment	A61N5/10	In the scheme	5,547
A61N2005/1094	Shielding, protecting against radiation	A61N5/10	In the scheme	5,135
A61K51/1045	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants	A61K51/00	In the scheme	5,106
A61N2005/1074	Details of the control system, e.g. user interfaces	A61N5/10	In the scheme	5,088
C07B59/00	Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se	C07B59/00	In the scheme	5,020
G01T1/161	Applications in the field of nuclear medicine, e.g. in vivo counting	G01T1/161	In the scheme	4,800
A61N2005/1098	Enhancing the effect of the particle by an injected agent or implanted device	A61N5/10	In the scheme	4,681
A61K51/0402	Organic compounds carboxylic acid carriers, fatty acids	A61K51/00	In the scheme	4,507
A61N5/1042	X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy with spatial modulation of the radiation beam within the treatment head	A61N5/10	In the scheme	4,467
A61K51/0459	Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine	A61K51/00	In the scheme	4,442
A61K51/0478	Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3	A61K51/00	In the scheme	4,437
A61N5/1045	X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy with spatial modulation of the radiation beam within the treatment head using a multi-leaf collimator, e.g. for intensity modulated radiation therapy or IMRT	A61N5/10	In the scheme	4,428
A61N5/1075	Monitoring, verifying, controlling systems and methods for testing, calibrating, or quality assurance of the radiation treatment apparatus	A61N5/10	In the scheme	4,356
A61K51/0491	Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers	A61K51/00	In the scheme	4,188
A61N2005/1097	Means for immobilizing the patient	A61N5/10	In the scheme	4,087
A61N2005/1055	Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using magnetic resonance imaging [MRI]	A61N5/10	In the scheme	3,916
A61N5/1027	Interstitial radiation therapy	A61N5/10	In the scheme	3,875
C07B59/004	Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium	C07B59/00	In the scheme	3,858
H05H6/00	Targets for producing nuclear reactions	H05H6/00	In the scheme	3,625
G01T1/1642	Static instruments for imaging the distribution of radioactivity in one or two dimensions using one or several scintillating elements; Radio-isotope cameras using a scintillation crystal and position sensing photodetector arrays, e.g. ANGER cameras	G01T1/161	In the scheme	3,601
A61K51/10	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody	A61K51/00	In the scheme	3,538
A61N2005/109	Neutrons	A61N5/10	In the scheme	3,537
A61N2005/1095	Elements inserted into the radiation path within the system, e.g. filters or wedges	A61N5/10	In the scheme	3,479
A61N5/1037	Treatment planning systems taking into account the movement of the target, e.g. 4D-image based planning	A61N5/10	In the scheme	3,388
A61N5/1002	Intraluminal radiation therapy	A61N5/10	In the scheme	3,371
A61K51/1096	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications	A61K51/00	In the scheme	3,352
A61N2005/1092	Details	A61N5/10	In the scheme	3,160
A61N5/1064	Monitoring, verifying, controlling systems and methods for adjusting radiation treatment in response to monitoring	A61N5/10	In the scheme	3,050
A61N5/1043	Scanning the radiation beam, e.g. spot scanning or raster scanning	A61N5/10	In the scheme	3,044
G21G4/08	Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application	G21G	In the scheme	2,996
A61K51/0453	Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole	A61K51/00	In the scheme	2,956
G21G1/10	Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators by bombardment with electrically charged particles	G21G	In the scheme	2,799
G21G1/001	Recovery of specific isotopes from irradiated targets	G21G	In the scheme	2,798
A61N5/1065	Beam adjustment	A61N5/10	In the scheme	2,730
A61N2005/1089	Electrons	A61N5/10	In the scheme	2,724
A61N2005/1059	Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using cameras imaging the patient	A61N5/10	In the scheme	2,703
A61K51/1282	Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents	A61K51/00	In the scheme	2,693
G21G1/0005	Isotope delivery systems	G21G	In the scheme	2,683
A61K51/0406	Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines	A61K51/00	In the scheme	2,670
A61K51/1244	Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles	A61K51/00	In the scheme	2,579
C07B59/008	Peptides; Proteins	C07B59/00	In the scheme	2,530
A61K51/065	Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules	A61K51/00	In the scheme	2,491
A61N5/107	Target adjustment, e.g. moving the patient support in real time, i.e. during treatment	A61N5/10	In the scheme	2,430
G01T1/1648	Ancillary equipment for scintillation cameras, e.g. reference markers, devices for removing motion artifacts, calibration devices	G01T1/161	In the scheme	2,383
G01T1/1644	Static instruments for imaging the distribution of radioactivity in one or two dimensions using one or several scintillating elements; Radio-isotope cameras using an array of optically separate scintillation elements permitting direct location of scintillations	G01T1/161	In the scheme	2,364
A61K51/1018	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans	A61K51/00	In the scheme	2,251
A61K51/083	Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide	A61K51/00	In the scheme	2,249
A61N5/1069	Target adjustment, e.g. moving the patient support	A61N5/10	In the scheme	2,207
A61N2005/1024	Seeds	A61N5/10	In the scheme	2,180
A61N5/1038	Treatment planning systems taking into account previously administered plans applied to the same patient, i.e. adaptive radiotherapy	A61N5/10	In the scheme	2,150
G21G4/02	Neutron sources	G21G	In the scheme	2,035
A61N2005/1054	Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using a portal imaging system	A61N5/10	In the scheme	2,030
G01T1/1647	Processing of scintigraphic data	G01T1/161	In the scheme	2,015
A61N2005/1076	Monitoring, verifying, controlling systems and methods for testing, calibrating, or quality assurance of the radiation treatment apparatus using a dummy object placed in the radiation field, e.g. phantom	A61N5/10	In the scheme	1,968
A61K51/082	Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide	A61K51/00	In the scheme	1,965
A61K51/02	Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus	A61K51/00	In the scheme	1,949
A61K51/0489	Phosphates or phosphonates, e.g. bone-seeking phosphonates	A61K51/00	In the scheme	1,850
A61N2005/1052	Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using positron emission tomography [PET] single photon emission computer tomography [SPECT] imaging	A61N5/10	In the scheme	1,834
G21G1/02	Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes in nuclear reactors	G21G	In the scheme	1,833
H05H13/04	Synchrotrons	H05H13/00	In the scheme	1,753
A61K51/1072	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate	A61K51/00	In the scheme	1,741
A61N5/1084	Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives	A61N5/10	In the scheme	1,732
G21G2001/0094	Other isotopes not provided for in the groups listed above	G21G	In the scheme	1,708
H05H13/005	Cyclotrons	H05H13/00	In the scheme	1,698
A61K51/06	Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules	A61K51/00	In the scheme	1,692
A61K51/1051	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin	A61K51/00	In the scheme	1,683
A61N5/1047	X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy with spatial modulation of the radiation beam within the treatment head using a multi-leaf collimator, e.g. for intensity modulated radiation therapy or IMRT with movement of the radiation head during application of radiation, e.g. for intensity modulated arc therapy or IMAT	A61N5/10	In the scheme	1,659
A61K51/12	Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules	A61K51/00	In the scheme	1,652
A61N2005/1021	Radioactive fluid	A61N5/10	In the scheme	1,639
A61N2005/1091	Kilovoltage or orthovoltage range photons	A61N5/10	In the scheme	1,609
A61N2005/1051	Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using an active marker	A61N5/10	In the scheme	1,568
A61K51/121	Solutions, i.e. homogeneous liquid formulation	A61K51/00	In the scheme	1,564
A61K51/1251	Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules	A61K51/00	In the scheme	1,514
A61N2005/105	Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using a laser alignment system	A61N5/10	In the scheme	1,485
A61K51/0446	Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil	A61K51/00	In the scheme	1,474
A61N5/1014	Intracavitary radiation therapy	A61N5/10	In the scheme	1,461
A61N2005/1019	Sources therefor	A61N5/10	In the scheme	1,444
A61N2005/1058	Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using ultrasound imaging	A61N5/10	In the scheme	1,400
G21G1/06	Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators by neutron irradiation	G21G	In the scheme	1,379
A61N5/1015	Treatment of resected cavities created by surgery, e.g. lumpectomy	A61N5/10	In the scheme	1,317
H05H13/00	Magnetic resonance accelerators; Cyclotrons	H05H13/00	In the scheme	1,300
A61N2005/1008	Apparatus for temporary insertion of sources, e.g. afterloaders	A61N5/10	In the scheme	1,276
G21G4/06	Radioactive sources other than neutron sources characterised by constructional features	G21G	In the scheme	1,265
A61N2005/1034	Monte Carlo type methods; particle tracking	A61N5/10	In the scheme	1,203
A61N5/1068	Gating the beam as a function of a physiological signal	A61N5/10	In the scheme	1,163
A61N5/1078	Fixed beam systems	A61N5/10	In the scheme	1,152
A61K51/1255	Granulates, agglomerates, microspheres	A61K51/00	In the scheme	1,117
A61K51/0474	Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group	A61K51/00	In the scheme	1,096
A61N2005/1062	Monitoring, verifying, controlling systems and methods for verifying the position of the patient with respect to the radiation beam using an x-ray imaging system having a separate imaging source using virtual X-ray images, e.g. digitally reconstructed radiographs [DRR]	A61N5/10	In the scheme	1,079
A61N2005/1041	Treatment planning systems using a library of previously administered radiation treatment applied to other patients	A61N5/10	In the scheme	1,073
A61N5/1082	Rotating beam systems with a specific mechanical construction, e.g. gantries having multiple beam rotation axes	A61N5/10	In the scheme	1,072
A61N5/1083	Robot arm beam systems	A61N5/10	In the scheme	1,065
A61K51/1048	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen	A61K51/00	In the scheme	1,061
A61K51/025	Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds	A61K51/00	In the scheme	1,060
A61K51/1234	Liposomes	A61K51/00	In the scheme	1,054
A61K51/081	Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin	A61K51/00	In the scheme	1,047
C07B59/005	Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids	C07B59/00	In the scheme	1,047
A61K51/103	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators	A61K51/00	In the scheme	1,045
A61K51/1057	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas	A61K51/00	In the scheme	1,020
A61K51/1075	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme	A61K51/00	In the scheme	1,014
A61N2005/1072	Monitoring, verifying, controlling systems and methods for verifying the dose delivered by the treatment plan taking into account movement of the target	A61N5/10	In the scheme	1,006
A61N2005/1012	Templates or grids for guiding the introduction of sources	A61N5/10	In the scheme	988
A61N2005/1011	Apparatus for permanent insertion of sources	A61N5/10	In the scheme	984
A61K51/1217	Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols	A61K51/00	In the scheme	983
A61N5/1079	Sharing a beam by multiple treatment stations	A61N5/10	In the scheme	975
A61N2005/1085	X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient	A61N5/10	In the scheme	956
G21G4/04	Radioactive sources other than neutron sources	G21G	In the scheme	914
A61K51/1241	Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins	A61K51/00	In the scheme	912
A61K51/0485	Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal	A61K51/00	In the scheme	907
A61K51/1069	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma	A61K51/00	In the scheme	906
A61K51/1021	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons	A61K51/00	In the scheme	891
A61N5/1036	Leaf sequencing algorithms	A61N5/10	In the scheme	880
G21G1/04	Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators	G21G	In the scheme	877
A61K51/1206	Administration of radioactive gases, aerosols or breath tests	A61K51/00	In the scheme	871
A61K51/1063	Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines	A61K51/00	In the scheme	865
A61K51/1213	Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature	A61K51/00	In the scheme	864
A61N5/1016	Gynaecological radiation therapy	A61N5/10	In the scheme	864
A61N2005/1023	Means for creating a row of seeds, e.g. spacers	A61N5/10	In the scheme	863
A61K51/1203	Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors	A61K51/00	In the scheme	857
A61N2005/1096	Elements inserted into the radiation path placed on the patient, e.g. bags, bolus, compensators	A61N5/10	In the scheme	851
G21G1/00	Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes	G21G	In the scheme	840
A61K51/048	DTPA (diethylenetriamine tetraacetic acid)	A61K51/00	In the scheme	832
H05H13/02	Synchrocyclotrons, i.e. frequency modulated cyclotrons	H05H13/00	In the scheme	824
A61K51/0495	Pretargeting	A61K51/00	In the scheme	812
A61K51/0463	Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines	A61K51/00	In the scheme	799

Match: Direct

The capability is itself a technology or a kind of physical system, and the classification names it. Emission tomography is CPC only; cyclotrons and radiotherapy also serve non-isotope uses. The crosswalk is a first pass that nobody has reviewed.

Nuclear Medicine & Radioisotope Technologies

Year by year

Volume

Share by country

Country leaderboard

Ten largest

Applicants

Global

United States

China

Japan

Germany

South Korea

Similar capabilities

Crosswalk

Other capabilities in Biotechnology & Health Technologies